EMEA doubled drug assessments in 2006
The European Medicines Agency (EMEA) says it reviewed a record number of new drugs in 2006, nearly doubling the previous year's total of 40.
The European Medicines Agency (EMEA) says it reviewed a record number of new drugs in 2006, nearly doubling the previous year's total of 40.
The Agency assessed 77 applications for marketing approval for new drugs in 2006, and said in its report that a record 51 positive opinions were issued by the Committee for Medicinal Products for Human Use (CHMP) in 2006.
The agency also handled record numbers of post-authorisation-variation applications and requests for scientific advice, it added.
EMEA executive director Thomas Loenngren said: 'I am very pleased by our performance in 2006, which was one of the busiest years ever, and the first full year in which we operated under the terms of the revised pharmaceutical legislation.'
Looking to 2008, the EMEA said its management board had adopted the Agency's draft work programme for 2008.